Could a common liver drug replace steroids for immunotherapy side effects?
NCT ID NCT07378761
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether ursodeoxycholic acid (UDCA), a drug already used for other liver conditions, can treat cholestatic hepatitis—a liver inflammation caused by immunotherapy—better than standard steroids. About 94 adults with cancer (excluding liver cancer) who develop this side effect will be randomly assigned to UDCA or steroids. The main goal is to see if liver function improves by at least 25% after 21 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ursodeoxycholic acid (UDCA)
- What this could lead to
- If UDCA works, it could offer a safer, effective alternative to steroids for treating liver side effects from immunotherapy, helping patients stay on their cancer treatment.
- What could go wrong
- This is a small, early-phase trial (94 people) that hasn't started yet. UDCA may not work as well as steroids, and some patients may still need steroids.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE-MEDIATED CHOLESTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
APHP Paul Brousse
Paris, France
-
CHU Bordeaux
Bordeaux, France
-
CHU Montpellier
Montpellier, France
-
CHU Poitiers
Poitiers, France
-
CHU Toulouse
Toulouse, France
-
HCL Croix Rousse
Lyon, France